


Welcome to the COVID-19 Provider Webinar

Friday, September 22, 2023

9AM – 10:30AM

Questions

During today's webinar, please use the Q&A panel to ask your questions so CDPH subject matter experts can respond directly.



Resource links will be
dropped into, “Chat”



Housekeeping

Reminder to Panelists:



Please mute yourself when not speaking.

Please monitor the Q&A panel for questions you may be able to answer.

Reminder to Attendees:



Today's session is being recorded. Access today's slides and archived presentations at:
[EZIZ COVID Education](#)



If you have post-webinar questions, please email leslie.amani@cdph.ca.gov

Agenda: Friday, September 22, 2023

No.	Item	Speaker	Time (AM)
1	Welcome and Announcements	Leslie Amani and Blanca Corona (CDPH)	9:00 – 9:05
2	Vaccine Administration Data	Hailey Maeda (CDPH)	9:05 – 9:10
3	CA COVID-19 Vaccination Program Close-out	Alan Hendrickson (CDPH)	9:10 – 9:15
4	Updated COVID-19 Vaccine	Caterina Liu, MD and Kate McHugh (CDPH)	9:15 – 9:30
5	COVID-19 Vaccine Access	Claudia Aguiluz and Edward Salaguinto, PharmD, RPh (CDPH)	9:30 – 9:40
6	Vaccine Management	Josh Pocus (My Turn) and Maria Volk (myCAvax)	9:40 – 9:50
7	Resources and Q&A	CDPH Subject Matter Experts	9:50 – 10:30

Thank you, California COVID-19 Vaccination Program Providers!

Announcements

Blanca Corona, CDPH

COVID-19 Vaccine Locations

WE CAN DO THIS | Vaccines.gov | Home | Find COVID-19 Vaccines | Find Flu Vaccines | Español | CDC

Need help finding a COVID-19 vaccine in the U.S.? Call [1-800-232-0233](tel:1-800-232-0233) (TTY [1-888-720-7489](tel:1-888-720-7489))

[Back to COVID-19 Search](#)

COVID-19 vaccine locations near 95816

with Moderna (12+ / 18+) or Pfizer-BioNTech (12+ / 18+)

Only show locations with:

- ☐ Appointments available
- ☐ Ability to vaccinate 6 months ▼
- ☐ All searched vaccines in stock
- ☐ Participating in Bridge Access Program

[Learn more about the Bridge Access Program](#)

Powered by **VaccineFinder**

1. [Walgreens Co. #15987](#) 0.5 miles

1020 29th St #140, Sacramento, CA 95816

✓ **In stock.** Check appointment availability:

- Moderna (12+ / 18+)
- Pfizer-BioNTech (12+ / 18+)

★ **Bridge Access Program Participant**

[Check Availability](#)

[Call 916-738-3300](tel:916-738-3300)

Walgreens Co. #15987

1020 29th St #140, Sacramento, CA 95816

[916-738-3300](tel:916-738-3300)

[View Additional Details](#)

Need help finding a COVID-19 vaccine in the U.S.? Call
[1-800-232-0233](tel:1-800-232-0233)
(TTY [1-888-720-7489](tel:1-888-720-7489))

WE CAN DO THIS | Vaccines.gov | Home | Find COVID-19 Vaccines | Find Flu Vaccines | Español | CDC

Need help finding a COVID-19 vaccine in the U.S.? Call [1-800-232-0233](tel:1-800-232-0233) (TTY [1-888-720-7489](tel:1-888-720-7489))

Find a COVID-19 vaccine near you

Use Vaccines.gov to find a location near you, then call or visit their website to make an appointment.

[Find COVID-19 Vaccines](#)

[I'm looking for flu vaccines](#) →

Powered by **VaccineFinder**



Upcoming COVID-19 Crucial Conversations Webinar

Topic: Talking with Patients about the Updated COVID-19 Vaccine

Description: Learn conversation methodologies for effectively talking with patients about the updated 2023-2024 COVID-19 vaccine.

Speaker: Dr. Alex McDonald, cofounder of [#ThisIsOurShot](#)

When: Wednesday, September 27, 2023

Time: 12PM - 1PM PT

Please register [here](#).



The graphic is a blue rectangular poster with white and orange text boxes. At the top left, a white speech bubble contains the text 'COVID-19 Crucial Conversations'. To the right of this is the California Department of Public Health logo. Below the speech bubble, a white rounded rectangle contains the text 'Upcoming Webinar: Talking with Patients about the Updated COVID-19 Vaccine'. Below this, it says 'Learn conversation methodologies for effectively talking with patients about the updated monovalent COVID-19 vaccine.' and 'Wednesday, September 27 12:00PM - 1:00PM PT'. At the bottom of this white box is an orange button that says 'Register here!'. To the right of the text box is a circular portrait of Dr. Alex McDonald, a man with glasses and a white lab coat. Below the portrait are two purple circular logos: one with '#THIS IS OUR SHOT' and another with '#VACU NATE YA'.

COVID-19 Crucial Conversations

California Department of Public Health

Upcoming Webinar:
Talking with Patients about the Updated COVID-19 Vaccine

Learn conversation methodologies for effectively talking with patients about the updated monovalent COVID-19 vaccine.

Wednesday, September 27
12:00PM - 1:00PM PT

Register here!

#THIS IS OUR SHOT #VACU NATE YA

Digital Vaccine Record

GET YOUR DIGITAL VACCINE RECORD



Private. Convenient. Secure.

What is a Digital Vaccine Record (DVR)?
Your Digital Vaccine Record (DVR) is an electronic vaccination record from the California Immunization Registry (CAIR) and is an official record of the state of California.

What information does the DVR include?
The DVR has your name, date of birth, vaccination dates, and the vaccines you received.

Where do I access my Digital Vaccine Record?
Visit myvaccinerecord.cdph.ca.gov to access your record. You will need to enter your first and last name, date of birth, and mobile number or email address. You will create a PIN which will be required to obtain your DVR when the link to your record is provided to you.


For more DVR questions, visit myvaccinerecord.cdph.ca.gov/faq or call 1-833-422-4255 (open M-F 8AM-8PM, SA-SU 8AM-5PM).

California Department of Public Health, Immunization Branch

IMM-1461 (3/9/23)

DVR Fact Sheet

OBTENGA SU REGISTRO DIGITAL DE VACUNACIÓN



PRIVADO. COVENIENTE. SEGURO.

Registro Digital de Vacunación (DVR)
Su Registro Digital de Vacunación (DVR, por sus siglas en inglés) es un registro electrónico de vacunación procedente del Registro de Vacunación de California (CAIR, por sus siglas en inglés) y es un registro oficial del estado de California.

¿Qué información incluye el DVR?
El DVR tiene su nombre, fecha de nacimiento, fechas de vacunación y las vacunas que recibió.

¿Dónde accedo mi Registro Digital de Vacunación?
Visite myvaccinerecord.cdph.ca.gov para acceder su registro. Necesita ingresar su primer nombre y apellido, fecha de nacimiento y número de celular o correo electrónico. Necesitará crear un PIN para poder obtener su DVR cuando se le proporcione el enlace a su registro.

¿Qué registros digitales puedo acceder desde el Portal DVR?
Hay dos tipos de registros a los que puede acceder desde el Portal DVR:

- **Código QR de COVID-19** que (cuando es escaneado por un lector de tarjetas SMART Health) mostrará la misma información que su tarjeta de papel de los CDC: su nombre, fecha de nacimiento, fechas de vacunación y las vacunas.
- **Registro de todas las vacunas** que informaron las farmacias y otros proveedores de salud a CAIR. Tome en cuenta que es posible que su historial de vacunación no se haya ingresado a CAIR.

Para más preguntas sobre el DVR, visite myvaccinerecord.cdph.ca.gov/faq-es/ o llame al 1-833-422-4255 (L—V 8AM-8PM, S-D 8AM-5PM).

California Department of Public Health, Immunization Branch

IMM-1461S (3/30/23)

Spanish Version

- To access their DVR, patients should visit the [Digital Vaccine Record \(DVR\) portal](https://myvaccinerecord.cdph.ca.gov) (myvaccinerecord.cdph.ca.gov)
- Flyers are also available in [Arabic](#), [Simplified Chinese](#) and [Traditional Chinese](#), [Korean](#), [Tagalog](#) and [Vietnamese](#).
- The DVR request form is also available in the languages listed above to support easy communication. Records are also printable in these languages! See our [DVR FAQs](#) for more information.

Guidance for Reporting to Vaccines.gov

Key Information:


- Providers agree to make their BAP location visible so eligible recipients (uninsured and underinsured) can find no-cost vaccines.
- No inventory reporting is required

CAIRS Help Desk

800-578-7889

CAIRHelpDesk@cdph.ca.gov

Monday- Friday, 8:00AM-5:00PM



Vaccine Administration Data

Hailey Maeda, CDPH


Vaccine Administration Summary

as of September 18, 2023

89,819,438

Total Doses Administered:


Daily Doses Administered: **Statewide**



8,590,102

Total Up-to-Date* Recipients:

Percent of Population Who Are Up-to-Date




* Current definition of Up-to-Date does not yet include the new recommendations for the 2023-2024 monovalent mRNA vaccine

** Decrease in vaccine doses administered due to data processing of 2023-2024 monovalent mRNA doses and bivalent mRNA COVID-19 vaccines no longer being recommended in the United States

2023-2024 mRNA Vaccine Uptake Perceptions

- About 43% of adults reported they will “definitely” or “probably” will get the new, updated COVID-19 vaccine
- In September 2022, 32% of adults reported they planned to get a bivalent booster ([Kaiser Family Foundation](#)) and 21% of US (and CA) adults went on to receive a bivalent booster ([CDC](#))

Intent to get new, updated COVID-19 vaccine, August 2023



A nationally representative sample of U.S. adults aged 18 years and older


IPSOS KnowledgePanel and NORC AmeriSpeak Omnibus Surveys, results from August 2023 (N=4,299), unpublished data

86

2023-2024 mRNA Vaccine Uptake Perceptions

- Over 60% of adults believe the flu vaccine is “completely” or “very” safe compared to 49% for COVID-19 vaccine
- 21% of adults believe the COVID-19 vaccines are “not at all safe” compared to 10% for the flu vaccine

Confidence in vaccine safety is higher for influenza and other routine adult vaccines than for COVID-19 vaccine, June 2023



Analysis limited to those who responded to all three survey questions (N=4,164). Omitted category of respondents who answered “not sure” is <1%.

A nationally representative sample of U.S. adults aged 18 years and older

IPSOS KnowledgePanel and NORC AmeriSpeak Omnibus Surveys, results from June 2023 (N=4,214), unpublished data

89

Data Summary

as of September 18, 2023

Key Metrics

89.8 million doses administered

| **+5K** doses administered

21.5% Statewide Up-to-Date

| **8.6 million** Up-to-Date recipients

System Notes

- Preparing for inclusion of new monovalent mRNA codes into snowflake tables
 - Metrics for new monovalent mRNA vaccine to be made available pending system updates- TBD
- Email cdphvaccinatedatateam@cdph.ca.gov for questions and comments

CA COVID-19 Vaccination Program Close-out



What to Do with Bivalent Pfizer & Moderna Products


- Quarantine deauthorized mRNA products to prevent administration errors!
- Report vaccine products as “Waste” in myCAvax and use “Other” to add comment “deauthorized”!
- Already marked inactive? Inactive locations can now report as of 9/12/23!
- Dispose of vaccines following practice protocols; vaccines may be disposed of in a pharmaceutical waste container, or a comingled pharmaceutical/Sharps waste container.
- Waste Reporting Deadline: Saturday, September 30, 2023, by 11:59PM

Manufacturer	Presentation	Unit of Sale NDC
ModernaTX Inc.	MDV5; 10-pack	80777-0282-99
ModernaTX Inc.	Ped 6m-5y; MDV2; 10pk	80777-0283-99
Pfizer Inc.	MDV6; 10-pack	59267-0304-02
Pfizer Inc.	SDV; 10pk	59267-1404-02
Pfizer Inc.	Ped 5y-11y; MDV10; 10pk	59267-0565-02
Pfizer Inc.	Ped 6m-4y; MDV10; 10pk	59267-0609-02

Continue to administer Novavax until the product is deauthorized!



myCAvax Waste Reporting Close-out Timeline



Waste Reporting Deadline:
September 30, 2023
11:59PM

“Starting strong is good. Finishing strong is epic!”
Robin Sharma



What to do with old ancillary supplies?

- Check if ancillary supplies are expired.
- If supplies are expired, dispose of them according to your clinic's waste management policies.
- If supplies are not expired, you can use them for other clinical activities, give them to other providers, or dispose of them
 - **Do not** send them out of the country!
- Shred old CDC COVID-19 vaccination cards.





Deauthorized COVID-19 Vaccine

Inventory Checklist

- Remove deauthorized products immediately to prevent administration errors.
- For deauthorized bivalent products: Report as “Waste” and use “Other” to add comment “deauthorized”; dispose of products following practice protocols (may be disposed of in a pharmaceutical waste container, or a comingled pharmaceutical/Sharps container).
- For nonviable updated COVID-19 vaccine: Report as “Waste” and return to McKesson; label as “nonviable vaccine”.

Managing Vaccine Inventory

About Inventory Management

Efforts to raise immunization levels in provider populations fall short if vaccine inventory is not managed to ensure viability. Vaccine inventory management is an essential practice that can prevent inadvertent vaccine loss due to temperature excursions.

Inventory Checklist

Inventory management tasks will quickly become part of your practice protocols to protect vaccines and minimize patient revaccination. Use this checklist to get started.

Store Vaccine under Recommended Temperatures

- ❑ Don't reject shipments; report shipment incidents in myCAvax the same day for resolution.
- ❑ Store vaccines under [manufacturer-recommended temperatures](#); label cartons with beyond-use dates as recommended by vaccine manufacturers.
- ❑ Group adult vaccines together and label in large letters (cartons, baskets, or shelf space) to ensure correct products are removed for administration.
- ❑ Record storage unit temperatures twice daily on a temperature log with current, min and max readings, or use [COVID-19 log](#); report temperature excursions daily in myCAvax.

Manage Expiration & Beyond-Use Dates

- ❑ Remove deauthorized products immediately to prevent administration errors.
- ❑ Rotate stock weekly (and when new shipments arrive) to ensure vaccines soon to expire are used first.
- ❑ As expiration dates draw near, check for extensions using Moderna | Novavax | Pfizer-BioNTech (TBD) expiry lookup tools; label product with updated dates to prevent errors.
- ❑ If unable to use before expiration, contact your local health department about transfers.
- ❑ Strictly comply with the manufacturer guidance on expiration dates.
- ❑ Remove spoiled or expired vaccine IMMEDIATELY to prevent administration errors.
- ❑ Do not use vaccine after the earlier of expiration or use-by date.

Report Vaccine Wastage


- ❑ Report doses spoiled, expired, or wasted in myCAvax.
- ❑ For deauthorized bivalent products: Report as “Waste” and use “Other” to add comment “deauthorized”; dispose of products following practice protocols (may be disposed of in a pharmaceutical waste container, or a comingled pharmaceutical/Sharps container).
- ❑ For nonviable 2023-24 COVID-19 vaccine: Report as “Waste” and return to McKesson; label as “nonviable vaccine”.

9/14/23

CDPH Inventory Checklist



Friday Provider Webinar Transition Timeline



2023-2024 Updated COVID-19 Vaccine



Clinical Update

Caterina Liu, M.D., CDPH

CDC Recommends Updated 2023-2024 COVID-19 Vaccines for Everyone 6 Months and Older

- The 2023–2024 formulation has been updated to a **monovalent** vaccine based on the Omicron XBB.1.5 sublineage of SARS-CoV-2
- Receiving an updated COVID-19 vaccine is safe and can restore protection against infections and severe disease
- **The bivalent formulation is no longer authorized (Original and Omicron BA.4/BA.5) and should not be used**
- Updated Novavax 2023-2024 formulation is under FDA review. Original Novavax vaccine is still authorized

General Clinical Recommendations

- **Ages 6 months through 4 years**

- Unvaccinated: 2 doses of updated Moderna COVID-19 vaccine or 3 doses of updated Pfizer-BioNTech COVID-19 vaccine
- Previously vaccinated: 1 or 2 doses of updated mRNA vaccine depending on number of previous doses

- **Ages 5 years and older**

- Receive 1 dose of updated (2023–2024 Formula) mRNA COVID-19 vaccine, regardless of previous vaccination history
- No additional doses recommended for people 65+ at this time

- Pediatric age transition: age-appropriate vaccine product and dosage recommended on day of vaccination, **except** for children who receive the Pfizer-BioNTech COVID-19 Vaccine and transition from age 4 years to 5 years during the 3-dose vaccination series (see [Transitioning from a younger to older age group](#))

Clinical Recommendations for Persons with Immunocompromise*

- **Persons with moderate or severe immunocompromise**
 - Unvaccinated: People 6 months of age and older are recommended to receive 3 homologous doses of either updated Pfizer-BioNTech or Moderna COVID-19 vaccine
 - Previously vaccinated: 1 or 2 doses of updated mRNA vaccine depending on number of previous doses
 - May receive 1 or more additional updated mRNA COVID-19 vaccine doses, at least 2 months after their last COVID-19 dose

[*Description of moderate and severe immunocompromising conditions and treatment](#)
[CDC Interim Clinical Considerations for Use of COVID-19 Vaccines in the United States](#)

Vaccine Interchangeability

- Homologous doses:
 - Children 6 months-4 years and immunocompromised individuals 6 months and older should receive all vaccine doses in their initial series from the same manufacturer
- Mix-and-match allowed for:
 - People 5 years of age and older who have received 1 or more doses of an mRNA vaccine (or 1+ doses of Novavax/Janssen for 12+)
 - IC people 5 years of age and older who have received 3 or more doses of an mRNA vaccine (or 1+ doses of Novavax/Janssen for 12+)
 - A different age-appropriate COVID-19 vaccine may be administered if: same vaccine not available, previous dose unknown, person would otherwise not complete the vaccination series, or person starts but unable to complete a vaccination series with the same COVID-19 vaccine due to a contraindication

Vaccine Coadministration

- In accordance with [General Best Practice Guidelines for Immunization](#), routine administration of all age-appropriate doses of vaccines simultaneously (coadministration) is recommended for children, adolescents, and adults if there are no contraindications at the time of the healthcare visit.
- Providers may simultaneously administer COVID-19, influenza, and respiratory syncytial virus (RSV) vaccines to eligible patients

Vaccination After COVID-19 Infection

- COVID-19 vaccination is recommended for everyone ages 6 months and older, regardless of a history of symptomatic or asymptomatic SARS-CoV-2 infection, including people with prolonged post-COVID-19 symptoms.
- People with known current SARS-CoV-2 infection should defer any COVID-19 vaccination at least until recovery from the acute illness (if symptoms were present) and [criteria](#) to discontinue isolation have been met.
- People who recently had SARS-CoV-2 infection may consider delaying a COVID-19 vaccine dose by 3 months from symptom onset or positive test (if infection was asymptomatic).

Updated Federal Resources

- CDC Materials

- [Interim Clinical Considerations for Use of COVID-19 Vaccines in the United States](#)
- [Stay Up to Date with COVID-19 Vaccines](#)

- Factsheets

- COVID-19 Vaccine Information Statements (VIS) for licensed products (Spikevax and Comirnaty) are expected soon. In the interim, please refer to the following FDA documents:
 - For licensed products
 - Spikevax, 12 years and older, [FDA Patient Package Insert](#)
 - Comirnaty, 12 years and older, [FDA Package Insert](#) (patient package insert not available)
 - For products still under FDA EUA
 - Moderna Pediatric, 6 months-11 years, [FDA EUA Factsheet](#)
 - Pfizer Pediatric, 6 months-11 years, [FDA EUA Factsheet](#)



Updated COVID-19 Vaccine Timing Guide 2023-2024

COVID-19 Vaccine Timing 2023-24 –Routine Schedule			
Age*	Vaccine	If unvaccinated:	If had any prior doses, give 2023-24 doses:
6 months–4 years†	Pfizer–Infant/Toddler	1st Dose → 3–8 weeks → 2nd Dose → ≥8 weeks → 3rd Dose	If 1 prior dose, then: 3–8 weeks 1 ≥8 weeks 2 If ≥2 prior doses, then: ≥8 weeks 1
	Moderna–Pediatric*	1st Dose → 4–8 weeks → 2nd Dose	If 1 prior dose, then: 1 month 1 If ≥2 prior doses then: 2 months 1
5–11 years	Moderna–Pediatric*	1 Dose	If 1 or more prior doses (of any of the 4 brands), then*: ≥2 months Updated 2023-24 Formulation Moderna/Pfizer
	Pfizer–Pediatric	1 Dose	
12+ years	Pfizer–Adol/Adult (Comirnaty)	1 Dose	
	Moderna–Adol/Adult (Spikevax)	1 Dose	
	Novavax (2021)	1st Dose → 3–8 weeks → 2nd Dose 2023-24 formulation coming soon!	

* See CDC recommendations for children transitioning from a younger to older age group.
† Children 6 months – 4 years should receive the same brand of the updated vaccine as the prior doses they received.
** An 8-week interval may be preferable for some people, especially for males 12–39 years.
* All Moderna doses 6 months – 11 years are 0.25 mL (25 mcg).
^ Janssen (J & J) vaccine has been deauthorized. Follow schedule for 12+ years for any prior doses.

View [Interim Clinical Considerations for Use of COVID-19 Vaccines](#) for details. Schedule is subject to change.

California Department of Public Health, Immunization Branch IMM-1396 (9/14/23) Page 1 of 2

COVID-19 Vaccine Timing 2023-24 if Moderately/Severely Immunocompromised			
Age	Vaccine	If unvaccinated:	If had any prior doses give 2023-24 doses:
6 months–4 years	Pfizer Infant/Toddler	1st Dose → 3 weeks → 2nd Dose → ≥8 weeks → 3rd Dose → ≥2 months → Optional Dose*	1 prior dose: 3 w 1 ≥8 w 2 ≥2 prior doses: ≥8 w 1 ≥2 m Optional Dose*
	Moderna–Pediatric	1st Dose → 4 weeks → 2nd Dose → ≥4 weeks → 3rd Dose → ≥2 months → Optional Dose*	1 prior dose: 4 w 1 ≥4 w 2 2 prior doses: ≥4 w 1 ≥2 m Optional Dose*
5–11 years	Moderna–Pediatric	1st Dose → 4 weeks → 2nd Dose → ≥4 weeks → 3rd Dose	≥2 m Optional Dose* (Moderna/Pfizer)
	Pfizer–Pediatric	1st Dose → 3 weeks → 2nd Dose → ≥4 weeks → 3rd Dose	1 prior dose: 3 w 1 ≥4 w 2 2 prior doses: ≥4 w 1 ≥2 m Optional Dose* (Moderna/Pfizer)
12+ years	Pfizer–Adol/Adult (Comirnaty)	1st Dose → 3 weeks → 2nd Dose → ≥4 weeks → 3rd Dose	1 prior dose: 3 w 1 ≥4 w 2 2 prior doses: ≥4 w 1 ≥2 m Optional Dose* (Moderna/Pfizer)
	Moderna–Adol/Adult (Spikevax)	1st Dose → 4 weeks → 2nd Dose → ≥4 weeks → 3rd Dose	1 prior dose: 4 w 1 ≥4 w 2 2 prior doses: ≥4 w 1 ≥2 m Optional Dose* (Moderna/Pfizer)
	Novavax (2021)	2023-24 formulation coming soon!	If 1 or more prior doses, then: ≥8 weeks Updated 2023-24 Formulation Moderna/Pfizer ≥2 m Optional Dose* (Moderna/Pfizer)

* An optional dose may be given ≥2 months after the last dose. Further doses may be given at the healthcare provider's discretion. See Table 2 for vial and dosage.
** Ages 5+ years may be given Moderna or Pfizer after ≥3 prior doses.

California Department of Public Health, Immunization Branch IMM-1396 (9/20/23) Page 2 of 2



COVID-19 Vaccine Product Guide - Updated

COVID-19 Vaccine Product Guide

Check vaccine labels and [FDA materials](#) before use to avoid mix-ups.
EUA fact sheets supersede info on vials and carton. Refer to [CDC Product Guide](#) for more information.

	Pfizer Infant/Toddler 6 months–4 years	Pfizer Pediatric 5–11 years	Pfizer Comirnaty 12+ years
	2023-24 Formula	2023-24 Formula	2023-24 Formula
Packaging	Yellow Cap	Blue Cap	Gray Cap
Doses Per Vial	3 doses	1 dose	1 dose
Carton Size	30 doses	10 doses	10 doses
NDC-Unit of Use (vial)	59267-4315-01	59267-4331-01	00069-2362-10
CVX Code	302	301	300
CPT Code	91318	91319	91320
Program Availability	VFC	VFC	VFC, BAP
Min. Standard Order*	30 doses	10 doses	10 doses
Storage Limits Before Puncture: Label vaccine with expiration and use-by dates.			
ULT	Until expiration date at -90°C to -60°C (-130°F to -76°F)		
Thermal Shipper			
Freezer			
Refrigerator	Up to 10 weeks at 2° to 8°C (36°F to 46°F). Write the date on carton—not to exceed expiration.		
Expiration Date	Check the label or Pfizer product website .		
Administration			
Diluent (supplied)	1.1 mL per vial	Do not dilute	Do not dilute
Dose Volume & Dose	0.3 mL 3 mcg dose	0.3 mL 10 mcg dose	0.3 mL 30 mcg dose
Refrigerator Thaw Time (Do not refreeze)	2 hours in carton (2° to 8°C/36°F to 46°F)		
Room Temp Thaw Time (Do not refreeze)	Vial: 30 minutes at up to 25°C (77°F)		
Total Time at Room Temp	Up to 12 hours (including thaw time) at 8°C to 25°C (46°F to 77°F)		
Storage Limits After Puncture (Multi-dose vials): Record puncture and use-by time on vial label.			
Use-By Limit (Discard Time After 1st Puncture)	Discard 12 hours after dilution. Keep at 2°C to 25°C (35°F to 77°F)	N/A	N/A

* Orders for privately purchased vaccines may have different order minimums.

California Department of Public Health, Immunization Branch IMM-1399 (9/14/23) Page 1 of 3

COVID-19 Vaccine Product Guide

Check vaccine labels and [FDA materials](#) before use to avoid mix-ups.
EUA fact sheets supersede info on vials and carton. Refer to [CDC Product Guide](#) for more information.

	Moderna Pediatric 6 months–11 years	Moderna Spikevax 12+ years	Moderna Spikevax 12+ years	Novavax Adol/Adult 12+ years
	2023-24 Product	2023-24 Product	2023-24 Product	2021 Product (new product coming soon)
Packaging	Dark Blue Cap	Dark Blue Cap	Syringe	Royal Blue Cap
Doses Per Vial	1 dose	1 dose	1 dose	5 doses
Carton Size	10 doses	10 doses	10 doses	50 doses
NDC-Unit of Use (vial)	80777-0287-07	80777-0102-04	80777-0102-01	80631-0102-01
CVX Code	311	312	312	211
CPT Code	91321	91322	91322	91304
Program Availability	VFC	VFC, BAP	TBD	TBD
Min. Standard Order*	10 doses	10 doses	TBD	TBD
Storage Limits Before Puncture: Label vaccine with expiration and use-by dates.				
ULT				
Thermal Shipper				
Freezer	Until expiration at -50°C to -15°C (-58°F to 5°F)			
Refrigerator	Up to 30 days (not to exceed expiration date) at 2–8°C (36–46°F)			Until expiration
Expiration Date	Check Moderna product website or QR code.			Check product website.
Administration				
Diluent (supplied)	Do not dilute			Do not dilute
Dose Volume & Dose	0.25 mL 25 mcg	0.5 mL 50mcg	0.5 mL 50mcg	0.5 mL 5 mcg
Refrigerator Thaw Time (Do not refreeze)	45 minutes for single dose vial or 1 hour for syringe at 2°C to 8°C (36°F to 46°F). Let stand at room temp for 15 min before administering.			N/A
Room Temp Thaw Time (Do not refreeze)	15 minutes for single dose vial or 45 minutes for syringe at 15° to 25°C (59° to 77°F)			N/A
Total Time at Room Temp	Store up to 24 hours at 8°C to 25°C (46°F to 77°F)			N/A
Storage Limits After Puncture (Multi-dose vials): Record use-by time on vial.				
Use-By Limit (Discard Time After 1st Puncture)	N/A. Discard after single use.			Discard 12 hours after puncture. Keep at 2° to 25°C (36° to 77°F)

* Orders for privately purchased vaccines may have different order minimums.

California Department of Public Health, Immunization Branch IMM-1399 (9/14/23) Page 2 of 3

COVID-19 Vaccine Product Guide

Do Not Use Deauthorized Products:
Use only COVID-19 vaccine products updated for 2023-24.

Pfizer		
Infant/Toddler 6 months–4 years	Pediatric 5–11 years	Adol/Adult 12+ years
2021 Monovalent	2021 Monovalent	2021 Monovalent

Moderna				
Infant/Toddler 6 months–5 years	Infant/Toddler 6 months–5 years	6 months+	Pediatric 6–11 years	Adol/Adult 12+ years
2021 Monovalent	2021 Monovalent	Bivalent	2021 Monovalent	2021 Monovalent

Janssen (J&J)
2021 Monovalent

California Department of Public Health, Immunization Branch IMM-1399 (9/14/23) Page 3 of 3



Upcoming ACIP Meeting

CDC Advisory Committee on Immunization Practices (ACIP)

Topic: Maternal RSV Vaccine

When: Friday, September 22, 2023

Time: 7AM, PST

[Webcast Link to Join](#)

[ACIP Meeting Agenda](#)

Storage and Handling

Katherine McHugh, CDPH

Commercialized **Spikevax** and **Moderna**

Presentations

- Spikevax, Ages 12+
 - Single dose vials. 0.5 mL injection volume.
 - Prefilled Syringes, 0.5 mL injection volume.
- Moderna COVID-19 Vaccine, Ages 6 months - 11years
 - Single dose vials. 0.25 mL injection volume.

Minimum Order

- 10 doses for government supplied vaccines (Note: minimum order may be larger if purchasing through a wholesaler, e.g., + 60 doses)



Commercialized Moderna (Spikevax)

- Storage (vials and prefilled syringes)
 - Long-term frozen storage
 - Refrigerated storage for up to 30 days BUD
 - Normal room temperature for up to 24 hours
- Offering returns?
 - Yes



Commercialized Novavax (coming soon?)

- Presentation
 - Ages 12+: 5 dose multi-dose vials. 0.5mL injection volume.
- Minimum Order
 - 10 doses, 2 vials
- Storage
 - Refrigerated expiry 9 months from date of manufacture
 - Always double check the expiration date against the lot number
- Offering returns? Yes, up to 100% for opened and unopened vials



Commercialized Pfizer and Comirnaty

- Presentations

- Pfizer COVID-19 Vaccine, 6 months – 4 years: Requires diluent (1.1 mL normal saline). 3 dose multi-dose vials. Yellow cap. 0.3 mL injection volume.
- Pfizer COVID-19 Vaccine, 5 years – 11 years: No diluent required. Single dose vials. Blue cap. 0.3 mL injection volume.
- Comirnaty, 12 years+: No diluent required. Single dose vials. Gray cap. 0.3 mL injection volume.

- Minimum Order

- 6 months – 4 years: 30 doses
- 5 years – 11 years: 10 doses (government supplied vaccine), 100 doses private purchase
- 12 years+: 10 doses (government supplied vaccine), 100 doses private purchase



Commercialized **Pfizer** (Comirnaty)

- Storage
 - Long-term storage at ultracold temperatures, if vaccine was received at ultracold temperatures expiry (12 to 18 months from date of manufacture)
 - Always double check the expiration date against the lot number
 - Short-term storage (10 weeks) at refrigerated temperatures (most wholesalers have said they plan to ship this way)
- Returns Offered?
 - Yes



Links to the EUA Fact Sheets/Package Inserts


- Comirnaty, 12 years plus: [Comirnaty Prescribing Information Highlights](#)
- Spikevax, 12 years plus: [Spikevax Prescribing Information Highlights](#)
- Moderna, ages 6 month to 11 years: [Moderna COVID-19 Vaccine \(2023-2024\) Fact Sheet EUA Highlights](#)
- Pfizer, ages 6 months to 11 years: [Pfizer BioNTech EUA Fact Sheet Highlights](#)



COVID-19 Vaccine Access



COVID-19 Vaccine Access and Ordering



COVID-19 Vaccines Transitioning to the VFC Program- what will change?

Insurance plans will cover the 2023-2024 COVID-19 vaccines immediately

- The Affordable Care Act (ACA) requires insurers to cover *most* ACIP-recommended vaccines without cost sharing by the *next* coverage year¹
 - COVID-19 vaccines are on recommended schedules since February 2023²
- Section 3203 of the CARES Act expedites coverage of **COVID-19 vaccines** beyond that which is required of most preventive services
 - As of January 5, 2021: “plans and issuers must cover COVID-19 vaccines and their administration without cost sharing **immediately** once the vaccine becomes authorized under an EUA or approved under a BLA, and according to the scope of the applicable EUA or BLA”³
- In July 2023, HHS issued guidance to payors to prepare to cover COVID-19 vaccination with the onset of COVID-19 vaccine commercialization⁴

1. 42 U.S. Code § 300gg-13 - Coverage of preventive health services: <https://www.law.cornell.edu/uscode/text/42/300gg-13>

2. CDC Immunization Schedules by Age: <https://www.cdc.gov/vaccines/schedules/hcp/index.html>



3. FAQs about Affordable Care Act Implementation Part 50: <https://www.dol.gov/sites/dolgov/files/EBSA/about-ebsa/our-activities/resource-center/faqs/aca-part-50.pdf>

4. CMS Administrator Brooks-LaSure Letter to Payors Regarding Coverage of COVID-19 Vaccines Post Commercialization, July 13 2023: <https://www.hhs.gov/about/news/2023/07/13/cms-administrator-brooks-lasure-letter-to-payors-regarding-coverage-covid-19-vaccines-post-commercialization.html>






Vaccine and Clinic Eligibility Guidelines by Funding Source

For Health Departments and CDPH Approved Health Department Authorized Sites (Effective 10/01/2023 through 9/30/2024)



Program	 VFC Vaccines for Children Program	 BAP Bridge Access Program	317 Local Health Departments ¹	VFA Vaccines for Adults Program	SGF State General Funds ²
Funding	VFC-Federal entitlement program for eligible children. Funds are used to pay for vaccines recommended by ACIP and approved into the VFC program.	BAP-Limited federal funds (Section 317) for eligible adult populations to maintain access to COVID-19 vaccines through existing public health infrastructure.	317-Limited federal funds (Section 317) used to pay for adult vaccines recommended by ACIP and support limited vaccine supply for outbreak activities via Public Health Departments.	317-Limited federal funds (Section 317) used to pay for adult vaccines recommended by ACIP and included in the VFA Program.	Limited state funds for the purchase of vaccines to prevent respiratory illness.
Age and Eligibility	Children Birth–18 years: <ul style="list-style-type: none"> • Medi-Cal/CHDP eligible • Uninsured (no health insurance) • American Indian or Alaskan Native • Underinsured: health insurance does not cover vaccines (ONLY if the LHD has a FQHC or RHC designation). 	Adults 19 years and older: <ul style="list-style-type: none"> • Uninsured (no health insurance) • Underinsured (vaccines are not covered by insurance) 	Adults 19 years and older: <ul style="list-style-type: none"> • Uninsured adults (no health insurance) • Underinsured adults (vaccines are not covered by insurance) • Insured exceptions-Adults part of outbreak control, post-exposure prophylaxis, or disaster relief efforts as approved by CDPH & LHDs. • Household contacts or sexual contacts of HBsAg+ pregnant woman 	Adults 19 years and older: <ul style="list-style-type: none"> • Uninsured adults (no health insurance) • Underinsured adults (vaccines are not covered by insurance) 	All ages: <ul style="list-style-type: none"> • No restrictions
Clinic Type	<ul style="list-style-type: none"> • Federally Qualified Health Center (FQHC), Rural Health Center (RHC), and State-licensed • Community Health Centers • Health Department and CDPH Approved Health Department Authorized Sites • Juvenile halls/youth correctional facilities • Private providers, School-based clinic, Hospitals, Pharmacies (pilot program) 	<ul style="list-style-type: none"> • Health Department Clinics • Federally Qualified Health Center (FQHC), Rural Health Center (RHC) • Tribal Clinics • Indian Health Services • Limited sites designated by Local Health Department as BAP Provider 	<ul style="list-style-type: none"> • Health Department and CDPH Approved Health Department Authorized Sites (HDAS) • Juvenile halls/youth correctional facilities (for 19-25 years of age) 	<ul style="list-style-type: none"> • VFC enrolled Federally Qualified Health Center (FQHC), Rural Health Center (RHC) 	<ul style="list-style-type: none"> • State-licensed Community Health Centers • Federally Qualified Health Center (FQHC), Rural Health Center (RHC) • Health Department and CDPH Approved Health Department Authorized Sites (HDAS) • Private provider • School-based clinic



Program	Vaccines for Children Program (VFC)	Bridge Access Program (BAP)	317 Local Health Dept.	Vaccines for Adults Program (VFA)	State General Funds (SGF)
Vaccines	<ul style="list-style-type: none"> COVID-19 DTaP Hepatitis A Hepatitis B Hib HPV Influenza Meningococcal Conjugate (MenACWY) Meningococcal B (MenB) MMR Pneumococcal Conjugate (PCV15 and PCV20) Pneumococcal Polysaccharide (PPSV23) Polio (IPV) Rotavirus RSV (coming soon) Td, Tdap Varicella 	<ul style="list-style-type: none"> COVID-19 	<ul style="list-style-type: none"> Hepatitis A Hepatitis B³ HPV Meningococcal Conjugate (MenACWY) MMR Pneumococcal Conjugate (PCV20) Td only when Tdap is not indicated⁴ Tdap Varicella Zoster 	<ul style="list-style-type: none"> Hepatitis A Hepatitis B HPV Meningococcal Conjugate (MenACWY) MMR Pneumococcal Conjugate (PCV20) Td only when Tdap is not indicated Tdap Varicella Zoster 	<ul style="list-style-type: none"> Influenza Tdap (children only)
Ordering Website		 California Vaccine Management System			 California Vaccine Management System for flu vaccine (refer to your LHD for other vaccines)


1. Fully insured children and adults are not eligible to receive 317 vaccine routinely (adults enrolled in Medi-Cal/Medi-Cal managed care plans are considered fully insured). 317 vaccine may not be used in travel clinic settings.
2. Depending on funding, State General Fund vaccines may vary.
3. Adults with Medicare Part B (without Part D) are eligible if they are at low-risk for Hepatitis B. See [VFA Eligibility Based on Insurance Status](https://eziz.org/assets/docs/IMM-1247.pdf) (EZIZ.org/assets/docs/IMM-1247.pdf) for more details.
4. Adults with Medicare Part B (without Part D) are eligible if they are receiving Td as a routine vaccine (i.e., do not have a wound). See [VFA Eligibility Based on Insurance Status](https://eziz.org/assets/docs/IMM-1247.pdf) (EZIZ.org/assets/docs/IMM-1247.pdf) for more details.

COVID-19 Vaccine Transition to Commercialization

Vaccine availability for pediatric and adult populations to follow current models for non-COVID-19 vaccines upon COVID-19 Commercialization, post sunset of the USG COVID-19 Program.

Adult populations:

- Anticipate **limited** vaccine supply will be made available through the **CA Bridge Access Program (BAP)** for uninsured/under insured adults.
- Bridge Access Program for Retail Pharmacies will also support adult uninsured/underinsured vaccination
- Vaccines for insured adults will be private supply, obtained via established processes, like non-COVID vaccines.



Bridge Access Program (BAP)

Get No-Cost COVID-19 Vaccines Near You

You can get no-cost COVID-19 vaccines at healthcare providers, federally supported health centers, and retail pharmacy chains participating in the Bridge Access Program. Visit vaccines.gov to find providers that offer no-cost COVID-19 vaccines through the Bridge Access Program. Providers participating in the Bridge Access Program are contractually obligated to add vaccine availability to vaccines.gov. We expect reported availability to increase in the coming days.



Providers participating in the Bridge Access Program are contractually obligated to add vaccine availability to vaccines.gov.

Need help finding a COVID-19 vaccine in the U.S.? Call 1-800-232-0233 (TTY 1-888-720-7489)

Find a COVID-19 vaccine near you

Use Vaccines.gov to find a location near you, then call or visit their website to make an appointment.

[Find COVID-19 Vaccines](#)

[I'm looking for flu vaccines →](#)

Powered by VaccineFinder



Updated COVID-19 Vaccine Now Recommended for Children and Adults

The updated COVID-19 vaccine is available for children and adults. Updated COVID-19 vaccines are on the way to providers and availability will continue to increase in the coming weeks. [Search](#) to find a location near you. If you do not find a convenient location, check back later, or contact your health care provider or local health department. Learn more about [COVID-19 vaccine recommendations](#). CDC's [Bridge Access](#)

Respiratory syncytial virus (RSV)

Infants and older adults are more likely to develop severe RSV and need hospitalization. Vaccines are available to protect older adults from severe RSV. Monoclonal antibody products are available to protect infants and young children from severe RSV. Talk to your health care provider for information about RSV vaccination and monoclonal antibody products. Learn more about [RSV and RSV prevention](#).

COVID-19 Vaccine Access: Pharmacy

Edward Salaguinto, PharmD, RPh, CDPH



Bridge Access Program for Retail Pharmacies

- CVS administering doses within both their storefronts and Minute clinics.
- Walgreens administering doses in both their storefronts and plans for off-site events targeting areas of low access & low uptake.
- eTrueNorth (eTN) is a pharmacy aggregator that subcontracts with smaller pharmacies – Intended to reach lower-access areas without other coverage within the Bridge Access Program.
 - Additional subcontract negotiations between eTN and possible additional participating pharmacies are ongoing.
 - eTN is currently not enrolling other major chains, for now: Riteaid, Walmart, Kroger, Albertsons...
- CDC has given states options for coordination with contracted pharmacies for additional vaccination locations for the Bridge Access Program.
- Vaccines.gov - Find COVID-19 vaccine locations near you!
 - Site will indicate BAP participant, can also filter to only show BAP.





People with Medicare and Medi-Cal will also have access to COVID-19 vaccines at no cost

- COVID-19 vaccines covered under Medicare Part B without cost-sharing
- Inflation Reduction Act, passed in August 2022, includes key provisions:
 - Eliminates cost-sharing for all ACIP-recommended vaccines under Medi-Cal and Medicare Part D/equivalent plans
 - Guarantees that nearly 50 million Medicare beneficiaries and more than 80 million Medicaid beneficiaries will have access to all vaccines recommended by ACIP without cost-sharing
- All formulations of COVID-19 vaccine have been added to Medi-Cal's Contract Drug List.
 - **Magellan (third-party adjudicator): Currently updating files: new NDC's**
 - **Hoping to process normally as early as next week.**



Vaccine Management

Josh Pocus, My Turn, and Maria Volk, myCAvax

What's New in My Turn? – Release 43



New updates for My Turn Public and Clinic launched on
Wednesday, September 20, 2023!



Release Highlights



My Turn Public

When scheduling vaccine appointments, patients **will be able to view:**

- ✓ A filter on the clinics that serve either insured or uninsured / under-insured patients based on the health insurance question
- ✓ The clinic phone number in the 'Clinic Details' section
- ✓ An updated description on the clinic card that says "Please contact the clinic to confirm the patient's insurance is accepted"

When scheduling vaccine appointments, patients **will no longer be able to view:**

- ✓ The 'Yes, but cannot provide information' option on the health insurance question

Release Highlights



My Turn Clinic

Clinic Managers and Vaccine Administrators **will be able to:**

- ✓ Add multiple funding sources to a single vaccine inventory
- ✓ Select / update funding source on the Walk-in, IIS Edit, Inline / Bulk Upload, and Vaccine Administration flows
- ✓ Select vaccine supply for publicly or privately funded vaccines on clinic setup and clinic vaccine supply pages
- ✓ View / download new reports that include vaccine funding source and patient insurance information for billing purposes
- ✓ Add privately purchased vaccines to the clinic inventory

NOTE: New COVID-19 vaccines are not yet enabled in CAIR2. Therefore, Clinic Managers and Vaccine Administrators will encounter error messages regarding invalid NDC codes for appointments with new vaccines until CAIR2 adds them. To address this, CDPH plans to proceed with a priority release soon pending confirmation from CAIR2.

Set Vaccine Supply Funding Source During Clinic Creation

Clinic Managers must identify the funding source for their vaccine supply using the two new sections in the Clinic Creation flow, **‘Publicly Funded’** and **‘Privately Funded.’**

Publicly funded vaccines are purchased and distributed by government health agencies to be administered to eligible individuals without charging the patient or any insurance plans for the cost of the vaccine.

Privately funded vaccines are purchased by health care organizations and medical providers to be administered to individuals with commercial / private insurance (includes Medicare and Medi-Cal for adults) so that insurance companies reimburse for the costs associated with purchasing and administering the vaccine.

Vaccine Type

Please specify what type and brand of vaccine your clinic will offer. These values can be updated later in your clinic's vaccine inventory tab.

*Vaccine Type

☒ COVID-19
 ☐ Flu
 ☐ Vaccinia (mpox)

Vaccine brand(s)

Select all brands your clinic plans to have in inventory

COVID-19

Publicly Funded

☐ Pfizer (19+) - Publicly Funded
 ☐ Pfizer (12 - 18) - Publicly Funded
 ☐ Pfizer (6 - 11) - Publicly Funded
 ☐ Pfizer (6m - 4yrs) - Publicly Funded
 ☐ Moderna (19+) - Publicly Funded
 ☐ Moderna (12 - 18) - Publicly Funded
 ☐ Moderna (6m - 11yrs) - Publicly Funded
 ☐ Novavax (19+) - Publicly Funded
 ☐ Novavax (12 - 18) - Publicly Funded

Privately Funded

☐ Pfizer (12+) - Privately Funded
 ☐ Pfizer (6 - 11) - Privately Funded
 ☐ Pfizer (6m - 4yrs) - Privately Funded
 ☐ Moderna (12+) - Privately Funded
 ☐ Moderna (6m - 11yrs) - Privately Funded
 ☐ Novavax (12+) - Privately Funded

Clinic Settings

☐ Accept walk-in patients
 ☐ School vaccination site ⓘ

My Turn Public Product Roadmap



RECENTLY DEPLOYED

August 30th (R42)

Release 42

- ✓ Displayed full clinic closing date on the clinic card on the 'Select a Location' page
- ✓ Optimized and cleaned up backend user experience
- ✓ Updated Covid attestation copy / link on the 'Let's Get Started' page
- ✓ Removed health insurance description on the 'Patient Information' page
- ✓ Updated Public Call Center hours in the footer

CURRENT

September 20th (R43)

Release 43

Bridge Program Updates

- ✓ 'Select a Location' page:
 - ✓ Display the clinic phone number in the description field on the clinic card
 - ✓ Add a description text on the clinic card to remind patients to call the clinic to verify insurance acceptance (only for clinics with the insured vaccine supply)
 - ✓ Update copy about new BAP changes for Pharmacies
- ✓ 'Let's Get Started' page:
 - ✓ Add a description to the health insurance question

UPCOMING

October 25th (R44)

Release 44

- ✓ Display the clinic phone number on the clinic card - separate field
- ✓ Complete Public Site Refresh:
 - ✓ Add new navigation
 - ✓ Add new sitemap
 - ✓ Complete site refresh with new individual vaccinations Q&A pages (COVID-19, flu, and mpox)

My Turn Clinic Product Roadmap



RECENTLY DEPLOYED

August 30th (R42)

Release 42

- ✓ Created a new enrollment landing page
- ✓ Updated the enrollment training package
- ✓ Created a new community portal location enrollment menu and page
- ✓ Allowed non-myCAVax Providers a full Digital Enrollment process with enrollment screens, setup, and questions for enrollment in My Turn
- ✓ Allowed current Providers to enroll a new location in My Turn
- ✓ Enabled complete Digital Enrollment processes with the CDPH Enrollment team

CURRENT

September 20th (R43)

Release 43

Bridge Program Updates

- ✓ Add new tags on the Clinic Creation flow
- ✓ Make the 'Phone' field required
- ✓ Remove the option 'Yes but cannot provide information' on the health insurance question
 - ✓ Walk-in flow
 - ✓ VA flow
 - ✓ CSV / Inline Bulk Upload
- ✓ Update Digital Enrollment Flow

UPCOMING

October 25th (R44)

Release 44

- ✓ Begin development for Mass Vax (est. complete R45 / 46):
 - ✓ Official Name is TBD
 - ✓ Support all vaccines
- ✓ Fix Minor Bugs
- ✓ Update Race and Ethnicity values to New CAIR values:
 - ✓ IIS Tab
 - ✓ VA Flow
 - ✓ Bulk / CSV Upload

Updating Novavax Vaccine Inventory and Supply



Starting in myCAvax R43, Novavax vaccine will be available as publicly funded and privately funded supplies. Clinic Managers will need to add both supplies to their clinics to serve all patients.

Additionally, Clinic Managers will need to update the funding source on their existing Novavax vaccine inventories to reflect accurate funding for data quality.

What to Expect: My Turn and COVID-19



Privately-funded COVID-19 Vaccine Providers will need to:

Remove deauthorized vaccine supply. Do not remove deauthorized vaccine inventory to ensure continued historical vaccine appointment upload.



Add new vaccine supply* and inventory. Mark the supply for **insured** populations. Add / update a required clinic phone number and clinic availability.



Cancel / update all existing appointments for the deauthorized COVID-19 vaccine.



BAP Providers will need to:



Remove deauthorized vaccine supply. Do not remove deauthorized vaccine inventory to ensure continued historical vaccine appointment upload.



Add new vaccine supply* and inventory. Mark the supply for **uninsured** populations. Add / update a required clinic phone number and clinic availability.



Cancel / update all existing appointments for the deauthorized COVID-19 vaccine.

***NOTE:** Vaccine supply is now distinguished by insurance status and will impact public clinic tags and scheduling.

What's New in myCAvax? – Release 43



New updates for Providers launch today,
Friday, September 22, 2023!



Providers

Release Highlights



Providers will:

Shipment Incident

- ✓ See updated fields on the 'New Shipment Incident' pop-up window

Provider Community Site

- ✓ See an updated landing page displaying program tiles based on the Provider's program enrollment permissions
- ✓ See the 'Program Selected' dropdown on multiple pages based on the Provider's program enrollment permissions
- ✓ See orders on the 'Vaccine Orders' page based on the program selected from the 'Program Selected' dropdown
- ✓ See the COVID-19 or SGF 'Shipment Incidents' page based on the program selected from the 'Program Selected' dropdown
- ✓ See the COVID-19 or SGF 'Dashboard' page based on the program selected from the 'Program Selected' dropdown
- ✓ No longer see the 'Open Transfer Orders' pop-up window on the landing page

Vaccine Ordering – Provider

- ✓ See the COVID-19 or SGF 'Vaccine Order Request' page based on the program selected from the 'Program Selected' dropdown
- ✓ Be able to place vaccine order requests for SGF flu vaccine on the 'State General Fund - Vaccine Order Request' page
- ✓ Receive email notifications when their vaccine order request has been rejected or progressed to 'Fulfillment Pending'
- ✓ Receive a reminder email for an expiring COVID-19 or Outbreak draft order four days after the order creation date
- ✓ Have their draft orders deleted seven days after the order creation date; they will also receive a confirmation email for the same
- ✓ Be directed to the appropriate 'Vaccine Order Request' page when they click the 'Submit Order' button on a draft order

Location Account

- ✓ Have their location account's sub-status updated to 'On-Hold' and the 'Reason for On-Hold' field updated with the 'Provider Account Changes' value when the shipping address fields are updated

State General Fund – Vaccine Ordering



Providers will be able to place vaccine order requests for State General Fund flu vaccines in myCAvax beginning **Monday, September 25, 2023**. Providers must have an active program location to order vaccine.

myCAvax California Vaccine Management System

Home My Programs Vaccine Orders Shipment Incidents Reports myCAvax Dashboard More

Need help? Review the job aid(s) for [placing vaccine order requests](#), [product guide](#), [shipping cadence](#) and [managing storage units](#).

State General Fund - Vaccine Order Request

Step 1 - Select Account and Product

To change the program selected, navigate back to the [Vaccine Orders page](#).

Select Location, Provide Inventory and Doses Administered for Vaccine you Intend to Order

- Select the location account.
- Enter your On-Hand Inventory and Doses Administered **only for the vaccine(s) you intend to order**.

*Account

Comic Bookstore

Only enter values for products you want to order, otherwise leave fields blank.

Vaccine Products On-hand Inventory Doses administered Order size

Vaccine product	*Quantity	Lot number	Expiration Date	*Qty since last order	*Doses requested	
Fluzone Quadrivalent MDV (3 yrs - 100+ yrs) - 2023-2024 SGF	500	534	9/10/2024	300	250	Clear Row
Flublok SDS (18 yrs - 100+ yrs) - 10/box - 2023-2024 SGF					0	Clear Row

Chat with us

Upcoming State General Fund Ordering 101 Webinar



Are you a Provider who will be ordering State General Fund (SGF) flu vaccine in myCAvax? You are invited to join us for a one-hour 'State General Fund (SGF) Flu Vaccine Ordering 101 for Providers' session on **Monday, September 25, 2023**, from **11:00 AM – 12:00 PM PT** focused on basic navigation of myCAvax and placing vaccine orders. There will be an opportunity for Q&A with CDPH.

Please register [here](#) to attend.

myCAvax Release Roadmap



RECENTLY DEPLOYED

August 17th (R42)

Release 42

Bridge Access Program (BAP)

- ✓ Provided access to existing Providers to the BAP Enrollment flow to sign a new agreement
- ✓ Marked existing Providers as 'Pending BAP Enrollment'
- ✓ Updated Provider training with new BAP requirements
- ✓ Updated the welcome email to remove COVID-19 details

State General Fund

- ✓ Enhanced the SGF 'Order Fulfillment' process
- ✓ Enabled CDPH to select which program they are generating VtrckS files for
- ✓ Enhanced VtrckS to handle multiple programs
- ✓ Enhanced the 'Vaccine Order Review' calculation and 'Product Name' display

CURRENT

September 22nd (R43)

Release 43

Bridge Access Program (BAP)

- ✓ Enable existing Providers to be marked as 'Pending BAP Enrollment' when Program is open

State General Fund Community Site

- ✓ Enable Providers to create orders
- ✓ Enable Providers to create Shipment Incidents
- ✓ Enable Providers to view their 'SGF Dashboard'
- ✓ Enable Community users participating in multiple programs to see a new updated site

UPCOMING

October 20th (R44)

Release 44

Bridge Access Program (BAP)

- ✓ Separate COVID-19 and BAP transactions in the system

State General Fund Community Site

- ✓ Enable Providers to create Waste Events
- ✓ Enable Providers to create Excursions
- ✓ Enable Providers to view their SGF 'Locations' tab

Disposing Deauthorized Bivalent Product and Reporting Waste in myCAvax



Providers must dispose deauthorized bivalent vaccine immediately and report as waste in myCAvax. Release 42.1 went live on **Wednesday, September 13, 2023**, deactivating all USG COVID-19 Program Locations and enabling all Providers, regardless of COVID-19 Program Location status, to report waste and manage vaccine inventory.

Questions? Reach out to the Provider Call Center at providercallcenter@cdph.ca.gov or (833) 502 – 1245, **Monday through Friday from 8:00 AM – 5:00 PM PT.**



Bridge Access Program: Provider Eligibility Refresher

As a reminder, Providers serving uninsured / underinsured adults through Public Health Departments, Federally Qualified Health Centers (FQHCs) / Rural Health Centers, Tribal Clinics, and Indian Health Services sites are eligible for the Bridge Access Program (BAP).

Additional Providers deemed eligible by LHDs may also be able to enroll in BAP.






Bridge Access Program: Contact Updates and Completing Enrollment

If you are a BAP-eligible Provider who cannot access myCAvax, contact the Provider Call Center to confirm your account is active.

Once in myCAvax, if you do not see the enrollment pop-up window, contact the Provider Call Center to confirm your contact has the appropriate Program Role. Only Organization Vaccine Coordinators and Primary Vaccine Coordinators for BAP will be able to enroll their locations.

Slide Icon Key

Icon	Meaning
	This is to label slides that are referencing upcoming or existing functionality and how to use it in the system.
	This is to label slides that include important system reminders.
	This is to label slides that include tips and best practices to improve your system experience.

myCAvax – Known Issues – *Updated 9/15*



Known Issues

State General Funds (Flu) Ordering Emails Not Always Sent to the Correct Recipients

- ✓ In some instances, the correct recipients are being left out and not receiving emails relating to their flu orders.



Workaround / Next Steps

- ✓ Fix: 9/22. After 9/22, if you are not receiving emails for flu orders updates and believe you should, please contact the Provider Call Center at providercallcenter@cdph.ca.gov or call (833) 502 – 1245 (**Monday–Friday, 8–5 PM PT**) for support.

Resources

Leslie Amani, CDPH

COVID-19 Vaccine Support


Provider Call Center

Dedicated to medical providers and Local Health Departments in California, specifically addressing questions about State program requirements, enrollment, and vaccine distribution.

- For myCAvax Help Desk inquiries: myCAvax.hd@cdph.ca.gov
- For My Turn Clinic Help Desk inquiries: MyTurn.Clinic.HD@cdph.ca.gov
- For all other inquiries: providercallcenter@cdph.ca.gov
- Phone: (833) 502-1245, Monday through Friday from 8AM–5PM

myCAvax

- Virtual Assistant resolves many questions but will direct you to the Provider Call Center queue for live assistance!
- Knowledge Center houses key job aids and videos that are updated every release. Once logged in, you can access job aids from the myCAvax homepage (or at various places throughout the system) using the links as shown below.  Need help? View our job aids in the Knowledge Center, or contact us.




Commercialization at a Glance: Provider Transition Guide

Commercialization at a Glance: Provider Transition Guide

California COVID-19 Vaccination Program

Commercialization is the transition of COVID-19 medical countermeasures—vaccines, treatments, and test kits—previously purchased by the U.S. Government (USG) to established pathways of procurement, distribution, and payment by both public and private payers. This guide summarizes the [HHS Commercialization Transition Guide](#), [HHS Bridge Access Program Fact Sheet](#), and CDPH guidance as the USG prepares to stop distributing COVID-19 vaccines and vaccines transition to the commercial market. Updated topics highlighted below. Sections include:

- Fall Transition Timeline
- Sunsetting of the Federal COVID-19 Vaccination Program
- Commercialization of COVID-19 Vaccines
- Anticipated Vaccination Schedule for the Fall



Topic	Guidance	Effective Date
Section 1	Fall Transition Timeline	
	<div><div><div>Week of July 31, 2023</div><div>• CDC set vaccine thresholds to -0- in anticipation of decreased vaccine demand</div><div>• Providers were asked to order a 2-month vaccine supply to last until new products are approved by FDA</div><div>• Vaccine doses can still be ordered by States, but the processes, timing, and cadence for ordering processing will change. Based on doses ordered, we ask CDC for allocations, wait 1-3 days for doses, then transmit orders to CDC.</div></div><div><div>August 3-Early September</div><div>• Providers may still submit additional Small Orders if needed. But these are NOT sent to CDC. These are fulfilled locally/TPR.</div><div>• Larger orders are now only available to LHDs/MCEs.</div><div>• ALL healthcare providers are advised to begin planning, prebooking or procuring COVID-19 vaccine doses for privately insured individuals.</div><div>• States begin to plan closeout of USG COVID-19 Program, and implementation of much smaller Bridge Access Program, and addition of COVID-19 vaccines to VFC Programs.</div></div><div><div>TBD (expected early to mid-September)</div><div>• FDA decisions and amendments to Emergency Use Authorizations (EUAs) / Biologics License Applications (BLAs) Approve new products, and de-authorized current products.</div><div>• Concurrently, USG WILL discontinue distribution of current COVID-19 vaccine composition.</div><div>• Advisory Committee on Immunization Practices (ACIP) discussion on COVID-19 epidemiology and vaccine effectiveness and CDC recommendation.</div><div>• CDPH and LHDs work on BAP provider enrollment, and prepare for COVID-19 ordering for BAP Provider and VFC Providers.</div></div><div><div>TBD (ACIP Recommendation + 2 weeks=Late September/Early October)</div><div>• Fall vaccine availability for administration begins across all eligible age groups, with corresponding vaccine supply based on insurance coverage, and eligibility for providers participating in VFC or CA's Bridge Access Program.</div><div>• Providers will dispose of any remaining supply of de-authorized COVID-19 vaccines.</div></div></div>	

California Department of Public Health, IZ Branch

1

IMM-1467 (9/8/23)

CDPH has created a multiple-page “Commercialization Provider Transition Guide”.

The current information, and other resources, can be found on EZIZ.org using this link: [Commercialization at a Glance: Provider Transition Guide](#)

Updated: 9.8.23

COVID-19 Vaccine Provider FAQs

- Answers to provider questions
- Updated 9/14/2023
- Currently in its 132nd iteration!



Q: Following FDA authorization and CDC recommendations for the updated 2023-2024 COVID-19 vaccines, are bivalent mRNA COVID-19 vaccines still authorized for use?

A: No. Bivalent mRNA COVID-19 vaccines are no longer authorized for use. To prevent [vaccine administration errors](#), Providers should report and dispose of COVID-19 vaccines:

- Remove all bivalent mRNA COVID-19 vaccines from storage units regardless of expiration dates.
- Dispose of all bivalent mRNA COVID-19 vaccine vials in pharmaceutical waste containers or comingled pharmaceutical/sharps waste containers in accordance with local regulations and practice protocols for the disposal of regulated medical waste.
- Inactive providers can now report waste in myCAvax. The waste reporting deadline is Saturday, September 30, 2023, by 11:59PM. Report vaccine products as “Waste” in myCAvax and use “Other” to add comment “deauthorized.”

COVID-19 Vaccine FAQs v.132_9.14.23 1

COVID-19 Vaccine FAQs

For Providers administering COVID-19 vaccine.
Providers may also visit [EZIZ.org COVID-19 Webpage](#) and [EZIZ COVID-19 Resources](#) for information and updates.

Directions: [Click on a category to be directed to related FAQs.](#)

Contents

New and Updated FAQs	2
Vaccine Program Management.....	3
Vaccine Administration	4
Vaccine Storage & Handling	5
Reporting.....	5
Communication Resources.....	6





EZIZ COVID-19 Resources Page

Accessible from BAP Menu and
EZIZ Home Page!

Vaccine Information

- COVID-19 Vaccine Access & Ordering infographic
- COVID-19 Product & Timing Guides (**Updates coming soon!**)
- EUA Fact Sheets, package inserts, FDA pages, manufacturer websites
- General resources including guidance about fall products from FDA & CDC

Vaccine Administration

Communicating with Patients

- Resources for Patients
- Vaccine Confidence

COVID-19 Vaccine Resources

This landing page provides vaccine-specific resources to support all programs that supply COVID-19 vaccines. Relevant links are still being moved from the former EZIZ/COVID page. Please check back!

Vaccine Information

There is not a COVID-19 Vaccine Information Statement. Federal law allows up to 6 months for a new VIS to be used. EUA Fact Sheets for Recipients should be provided to patients at the time of vaccination for approved vaccine products. (See CDC guidance.)

- COVID-19 Vaccine Access & Ordering (Infographic)
- COVID-19 Vaccine Product Guide
- COVID-19 Vaccine Timing Guide | Spanish

Pfizer-BioNTech (2023-24 COVID-19 Vaccine, mRNA)

- Approval of Comirnaty for 12Y+: [Provider Letter](#) | [Package Insert](#) | [COMIRNATY \(FDA\)](#)
- Authorization under EUA for 6M-11Y: [Provider Letter](#) | [Fact Sheet for HCPs](#) | [Fact Sheet for Recipients & Caregivers](#) | [Pfizer-BioNTech COVID-19 Vaccine \(FDA\)](#)
- Websites: [Manufacturer](#) | [CDC Resources](#)

Moderna (2023-24 COVID-19 Vaccine, mRNA)

- Approval of Spikevax for 12Y+: [Provider Letter](#) | [Package Insert](#) | [FDA page](#)
- Authorization under EUA for 6M-11Y: [Provider Letter](#) | [Fact Sheet for HCPs](#) | [Fact Sheet for Recipients & Caregivers](#) | [Moderna COVID-19 Vaccine \(FDA\)](#)
- Websites: [Manufacturer](#) | [CDC Resources](#)

Novavax (2021 COVID-19 Vaccine, Adjuvanted)

- Authorization under EUA for 12Y+: [Fact Sheet for HCPs](#) | [Fact Sheet for Recipients & Caregivers](#) | [Novavax COVID-19 Vaccine \(FDA\)](#)
- Websites: [Manufacturer](#) | [CDC Resources](#)

General Resources

- CDC Recommends Updated COVID-19 Vaccine for Fall/Winter Virus Season (CDC)
- Updated mRNA COVID-19 Vaccines to Better Protect Against Currently Circulating Variants (FDA)
- Updated COVID-19 Vaccines for Use in the United States Beginning in Fall 2023 (FDA)
- Resources for the Fall Respiratory Illness Season (COVID-19, Flu and RSV) (FDA)

Vaccine Administration

- [Interim Clinical Considerations for Use of COVID-19 Vaccines \(CDC\)](#)
- [ACIP Recommended Immunization Schedules: Child and Adolescent](#) | [Adult \(CDC\)](#)
- [Coadministration of COVID-19 Vaccines \(CDC\)](#) | [Coadministration Tips \(graphic\)](#)
- [Reporting Adverse Events to VAERS](#)
- [Reporting Race & Ethnicity](#)
- [Tips to Ease Anxiety During Vaccination](#)
- [Vaccine Administration Checklist \(to be updated after FDA authorizations\)](#)
- [More Job Aids](#)

Communicating with Patients

- [COVID-19 Vaccine Resources for Patients](#)
- [COVID-19 Vaccine Confidence](#)



EZIZ BAP Landing Page!

1 From EZIZ Home Page:

2 BAP Vaccine Updates

3 Program Resources

- BAP at a Glance
- FAQs
- BAP Talking Points
- Infographic: Where can I get vaccines?

4 Program Information Menu

- [BAP Resources](#)
- [COVID-19 Vaccine Resources](#)
- [Implementation Timeline](#)

5 Provider Call Center



California's Vaccine Programs

VFC California Vaccines for Children Program	VFA California Vaccines for Adults Program	BAP California Bridge Access Program	317 Local Health Departments
--	--	--	--

Ordering & Vaccine Management

- MyVFCvaccines (for VFC and VFA)
- MyCAvax (for BAP and 317)


Storage Requirements

- Vaccine Storage Units
- Digital Data Loggers

Alerts!

2023 COVID-19 Vaccine

- CDC Recommends Updated 2023-2024 COVID-19 Vaccines for Everyone 6 Months and Older (9/13)
- New COVID-19 Vaccine Resources page



California Bridge Access Program

No-cost COVID-19 vaccines for uninsured & underinsured adults

Alerts!

CDPH is working closely with partner organizations to prepare all necessary resources for the Bridge Access Program. Please continue to check this webpage for updates.

Vaccine Updates

- CDC Recommends Updated 2023-2024 COVID-19 Vaccines for Everyone 6 Months and Older **NEW** September 13
- FDA Authorizes Updated COVID-19 mRNA Vaccines September 12
- September and October COVID-19 Vaccine Expiration Dates, September 7
- COVID-19 Vaccine Commercialization FAQs Updated 9/1
- Commercialization at a Glance: Provider Transition Guide Updated 9/8
- Check back for updates about BAP Vaccine ordering opening date!

Program Information

- BAP Overview
- BAP Resources
- COVID-19 Vaccine Resources
- Implementation Timeline
- CAIR Requirement
- Communications & Webinars

Provider Call Center

- Phone: (833) 502-1245
Hours: Mon-Fri, 8AM-5PM
- Email: Program Info, myCAvax Technical Support, MyTurn Technical Support

Program Overview

On April 18, 2023, the U.S. Department of Health and Human Services (HHS) announced the HHS Bridge Access Program (BAP) for COVID-19 Vaccines and Treatments. The BAP is a temporary measure connected to the commercialization of COVID-19 vaccines and treatment. It was created to prevent loss of access to free COVID-19 vaccines and treatment for uninsured and underinsured aged 19 years and older. The program will begin September 2023 and will end on December 31, 2024. More detailed information can be found at the CDC's Bridge Access Program Page, and in the CDPH BAP Requirements at a Glance.

The State program will utilize existing public health infrastructure, HRSA-supported health centers, and participating pharmacies via two major components:

1. Provide support for the existing public section vaccine safety net, implemented and maintained by state immunization programs and HRSA-supported health centers.
2. Create a funded partnership with pharmacy chains that will enable them to continue offering free COVID-19 vaccinations and treatments. This is a separate component under federal contract with key pharmacy chains. Participating chains will be able to provide COVID-19 vaccines to uninsured adult populations as well. All information on this landing page addresses the public health component.

Program Resources

- Requirements at a Glance (includes guidance and job aids)
- COVID-19 Commercialization FAQs on BAP (updated weekly)
- Talking Points for BAP COVID-19 Vaccines and Treatment (HCIRD)
- Infographic - Where Can Someone Get Vaccine? (CDC)
- California BAP Timeline




CA Bridge Access Program Provider Operations Manual


This manual provides step-by-step instructions and links to available resources.

Audience:

- Existing COVID-19 vaccine providers new to BAP
- New BAP organizations & locations



Startup Worksheet
(for new organizations & locations)





CA Bridge Access Program: At a Glance

Requirements at a Glance



This document will be continuously updated as information and new resources become available.


COVID-19 vaccine product and CDC's Vaccine Product Training will be posted after FDA authorization/CDC recommendation.

Who's Eligible: Providers serving uninsured/underinsured adults through public health departments, Federally Qualified Health Centers (FQHCs)/Rural Health Centers, tribal clinics, Indian Health Services sites, and additional providers deemed eligible by LHDs

What You Need to Know: The California Bridge Access Program provides no-cost COVID-19 vaccines to uninsured/underinsured adults (19 years and older) served by enrolled and approved providers. Vaccine supply is limited. Insured patients—including patients covered by Medicare and Medi-Cal—are NOT eligible. Providers must conduct eligibility screening and proper documentation with each administration to ensure vaccines go to eligible adults. Limited supplies of the updated monovalent (XBB subvariant) COVID-19 vaccine will be provided through two components of the state program:

Program Components:

- Public Health Component:** Coordinated by State Immunization Programs, in collaboration with existing public health infrastructure. CDPH will allocate to each LHD doses of COVID-19 vaccines based on federally provided vaccine purchase funding limits. Doses allocated will support vaccination of uninsured and under-insured populations at local health departments, FQHCs/RHCs, Tribal and IHS clinics, and other safety net providers selected by LHDs for enrollment in the CA Bridge Access Program.
- Pharmacy component:** Independently coordinated by CDC with 3 contracted pharmacy chains/organizations: CVS, Walgreens, and E-True North (for independent and other pharmacies), who will receive supplies replenished by the COVID-19 Vaccine manufacturers directly; the specific sites receiving vaccine are not yet determined, and enrollment information is still forthcoming. All information in this document addresses the public health component.

Topic	Requirements & Guidance	Resource Links
	What's new for existing COVID-19 providers? California's BAP Provider Participation Agreement replaces the federal COVID-19 Provider Agreement. While most requirements remain the same, look for orange stars identifying new requirements and job aids to assist you.	
Primary Documents	<ul style="list-style-type: none">BAP Provider Participation AgreementBAP Provider Operations Manual (and Startup Worksheet for new providers)COVID-19 Vaccine Commercialization FAQs	

Overview document links requirements and guidance to new resources!

Topics include:

- Provider Participation Agreement
- Required Vaccine Product Training
- Storage and Handling
- Reporting
- Vaccine Product Information
- Fact Sheets
- Much more to explore!

BAP Requirements at a Glance



New EZIZ BAP Resources Page!

Eligibility Screening & Documentation

Eligibility Based on Insurance Status

Bridge Access Program

A limited supply of COVID-19 vaccine will be made available through the Bridge Access Program for uninsured and underinsured adults (23 years and older) to prevent loss of access when vaccine transition to the commercial market. Insured patients—including patients covered by Medicare and Medi-Cal—are **NOT** eligible for the COVID-19 vaccines provided through this program. This temporary program will sunset at the end of 2024.

✓ Eligible for COVID-19 Vaccine through BAP (317 Funds)

Patient health insurance status:

- **Uninsured/No Insurance** (includes those who receive primary care through county safety net programs; these are **NOT** considered health insurance)
- **Underinsured** (has health insurance, but the insurance does not include any vaccines; insurance covers only selected vaccines; insurance does not provide first-dollar coverage for vaccines.)
- **Insurance NOT through Medi-Cal or Medicare** (only eligible for COVID-19 vaccines if **NOT** covered by patient's private insurance plan)¹

✗ Not Eligible for COVID-19 Vaccine through BAP (317 Funds)

Patient health insurance status:

- **Medi-Cal Fee-For-Service/Medi-Cal Managed Care** (not 1915(C) health plans)
- **Medicare Part B** (medical benefit) **AND** Part D (prescription drug benefit)
- **Medicare Part B Alone**
- **Medicare Part D Alone**
- **Insurance NOT through Medi-Cal or Medicare¹**

1. Fully insured adults whose insurance covers the cost of the vaccine(s) are **NOT** eligible for COVID-19 vaccine—even if the insurance includes a high deductible or co-pay, the plan's deductible has not been met, or the insurance has cost sharing.

California Department of Public Health, Immunization Branch | BAP-12473 (01/23)

Eligibility Cheat Sheet

317 (VFA & BAP) Eligibility Screening & Documentation Requirements

1. Screen for Eligibility

Eligibility screening must be conducted prior to the administration of any 317-funded vaccine (e.g., Vaccines for Adults and Bridge Access Programs). Eligibility is self-reported by the patient and verification of eligibility can be obtained verbally from the patient.

- ✓ **Eligible for VFA and/or BAP (COVID) vaccines if at least 19 years of age and**
 - 1. Has no insurance, or
 - 2. Is underinsured (public or private health insurance does not cover all vaccines or covers vaccines with a fixed dollar limit which has been reached)
- ✓ **Eligible for certain VFA vaccines if at least 19 years of age and**
 - 3. Has Medicare Part B, but **NOT** Part D; patient is eligible for:
 - Hep A
 - Hep B (if considered low risk for Hep B)
 - HPV, MMR, Varicella, and Zoster
 - Td (if no wound exposure) and Tdap
 - 4. Has Medicare Part D, but **NOT** Part B; patient is eligible for:
 - Hep B, PCV20

2. Document Patient's Eligibility

There are three important elements to include when you document a patient's eligibility:

1. Date of screening.
2. If patient is eligible for the Vaccines for Adults (VFA) and/or Bridge Access Program (BAP)
3. If patient is eligible **AND** at least 19 years of age, document which of the criterion above is met

3. Use a Compliant Record Keeping System

- **CAIR and Electronic Health/Medical Record (EHR/EMR)**
Note: If your practice's EHR/EMR does not capture all the necessary screening elements, they may be documented in the system's notes section.
- **CAIR and 317 Eligibility Screening Form (MM-1226)**

Make sure to maintain patient eligibility screening records for a minimum of 5 years. [Refer to the 317 CAIR Documentation Requirements.](#)

4. Communicate the Patient's Eligibility

All staff should be knowledgeable of eligibility. Ensure practice protocols are in place so vaccination know when to use 317-funded versus private vaccines.

California Department of Public Health, Immunization Branch | BAP-1476 (01/23)

Step-by-step Instructions
(includes options for reporting to CAIR)

317 (VFA & BAP) Eligibility Screening Record for Adult Patients

At each immunization visit, determine if patients are eligible for COVID-19 vaccines (if participating in the Bridge Access Program) and/or other routinely recommended vaccines through 317 funds (e.g., VFA).

Patient Information

Patient Name (Last, First, MI) _____ Date of Birth: _____

Provider Name: _____

Eligibility Criteria for 317-Funded Vaccines (e.g., VFA and BAP)

- ✓ **Eligible for VFA and/or BAP (COVID) vaccines if at least 19 years of age and**
 - 1. Has no insurance, or
 - 2. Is underinsured (public or private health insurance does not cover all vaccines or covers vaccines with a fixed dollar limit which has been reached)
- ✓ **Eligible for certain VFA vaccines if at least 19 years of age and**
 - 3. Has Medicare Part B, but **NOT** Part D; patient is eligible for:
 - Hep A
 - Hep B (if considered low risk for Hep B)
 - HPV, MMR, Varicella, and Zoster
 - Td (if no wound exposure) and Tdap
 - 4. Has Medicare Part D, but **NOT** Part B; patient is eligible for:
 - Hep B, PCV20

Document Patient's Eligibility

Write the screening data and check appropriate status. (Note: verification of responses is not required. Keep this record for at least 5 years and make it available to state or federal officials upon request.)

Screening Date	✓ Eligible for VFA and BAP (COVID) (No insurance)	✓ Eligible for VFA and BAP (COVID) (Underinsured)	✓ Eligible for some VFA vaccines (Medicare Part B or Part D only)	✗ Not Eligible for BAP (COVID) (Medicare Part B or Part D only)	✗ Not Eligible for VFA or BAP (COVID) (Both Medicare Part B & D or insurance pays for vaccines ¹)
	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/> Part B <input type="checkbox"/> Part D	<input type="checkbox"/> Part B <input type="checkbox"/> Part D	<input type="checkbox"/>
	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/> Part B <input type="checkbox"/> Part D	<input type="checkbox"/> Part B <input type="checkbox"/> Part D	<input type="checkbox"/>
	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/> Part B <input type="checkbox"/> Part D	<input type="checkbox"/> Part B <input type="checkbox"/> Part D	<input type="checkbox"/>
	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/> Part B <input type="checkbox"/> Part D	<input type="checkbox"/> Part B <input type="checkbox"/> Part D	<input type="checkbox"/>
	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/> Part B <input type="checkbox"/> Part D	<input type="checkbox"/> Part B <input type="checkbox"/> Part D	<input type="checkbox"/>
	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/> Part B <input type="checkbox"/> Part D	<input type="checkbox"/> Part B <input type="checkbox"/> Part D	<input type="checkbox"/>

¹Note: adults enrolled in Medi-Cal or Medi-Cal Managed Care are considered insured.

California Department of Public Health, Immunization Branch | BAP-1226 (01/23)

Screening Record
(for small practices with no EHR)

BAP Resources

Program Participation

- Requirements at a Glance
- Provider Operations Manual (POM)
- Required Vaccine Product Training

Eligibility Screening & Documentation

- BAP Eligibility Based on Insurance Status
- 317 (VFA & BAP) Eligibility Screening and Documentation Requirements
- 317 (VFA & BAP) Eligibility Screening Record | Spanish
- VFA & BAP Patient Vaccine Poster | Spanish
- Vaccine Program Eligibility Guidelines (for Community Health Centers)
- CAIR Requirement for Documenting 317-Funded Vaccines

2023-24 COVID-19 Vaccine Information

Please see EZIZ's COVID-19 Vaccine Resources for vaccine administration job aids plus materials from FDA, CDC and vaccine manufacturers.

BAP Resources



BAP Communications and Listservs

- Email Blanca Corona at Blanca.Corona@cdph.ca.gov to subscribe to the COVID-19 Vaccine Listserv or to receive help with troubleshooting.
- View [archived communications](#).
- Make sure you mark ProviderCallCenter@cdph.ca.gov as a “**safe sender**” on your email account to prevent communications from redirecting to your spam, junk, or other folder.
- **New BAP Listserv:** Providers, MCEs, and LHDs who are subscribed to the COVID-19 vaccine Listserv have been **automatically subscribed** to our new BAP Listserv, which went live earlier this week.



COVID-19 Therapeutics Resources

Type of Support


Description

Updated 8.31.23



Clinical Guidance

As of August 31, the COVID-19 Therapeutics Warmline: **1-866-268-4322 (866-COVID-CA)** is no longer staffed for provider COVID-19 Therapeutics questions. For general question Therapeutics questions, please email: COVIDRxProviders@cdph.ca.gov



General Information


[CDPH COVID-19 Treatments Webpage](#) (provides general information for healthcare providers, allocations, distribution and ordering, drug facts sheets, and additional resources)
[CDPH COVID-19 Treatments Job Aid](#) (questions and answers for the public on COVID-19 therapeutics)
[COVID-19 Therapeutics Best Practices Checklist](#) (testing, prescribing, dispensing, and more)
[Frequently Asked Questions document](#) for clinics, providers, and pharmacists



Locating Resources

Finding Providers and Test-to-Treat Sites

- [COVID-19 Therapeutics Locator](#) (arcgis.com)
- [Test-to-Treat](#) (hhs.gov)



[LHJ Therapeutics SharePoint](#)

Primary source for recorded webinars, slides, datasets and HPOP reporting information. (For access, email JEOCuser54@cdph.ca.gov)

- [Therapeutic Weekly Email Update](#) files (SharePoint)
- [CDPH Therapeutics HPOP Account Verification & Reporting](#) information



Questions

For general CDPH Therapeutics questions, please email COVIDRxProviders@cdph.ca.gov
For ordering, program inquiries, signing up new HPOP Accounts: please e-mail CDPHTherapeutics@cdph.ca.gov

CDPH Provider Webinars and Trainings




Week of September 25, 2023

	Monday 9/25	Tuesday 9/26	Wednesday 9/27	Thursday 9/28	Friday 9/29
Live Webinars and Training			COVID-19 Crucial Conversations Webinar: Talking with Patients about the Updated COVID-19 Vaccine 12:00 pm – 1:00 pm		COVID-19 Weekly Provider Webinar Series 9:00 am – 10:30 am
View On Demand	<ul style="list-style-type: none"> Intro to My Turn Onboarding (v. 1/4/22) Latest Features in My Turn (Requires My Turn Login) CDPH Weekly Provider Webinars Archived Recordings and Slides 		<ul style="list-style-type: none"> myCAvax Release Notes for LHJs and CDPH Users (Requires myCAvax Login) Latest Features in myCAvax for Providers (Requires myCAvax Login) COVID-19 Crucial Conversations Archived Webinars and Slides 		<ul style="list-style-type: none"> Moderna COVID-19 Vaccine Resources for Providers CDC COVID-19 Vaccine Webinar Series California Immunization Coalition COVID Conversation Series AIM Vaccine Confidence Toolkit Webinar Series
Help	Help Desk myCAvax Help Desk Email: mycavax.hd@cdph.ca.gov My Turn Help Desk Email: myturn.clinic.hd@cdph.ca.gov My Turn Onboarding Email: myturnonboarding@cdph.ca.gov		General CDPH Provider Call Center: 1-833-502-1245, 8am-5pm, Mon-Fri Email: providercallcenter@cdph.ca.gov Vaccines: COVID-19 Vaccines Therapeutics: COVID-19 Therapeutics		Mpox Email: stdcb@cdph.ca.gov General Website: Mpox Website Vaccines: Mpox Vaccines Website

Questions

During today's session, please use the Q&A panel to ask your questions so CDPH subject matter experts can respond directly.



Upcoming Opportunities



Friday



Provider Celebration Webinar

Next session: Friday, September 29, 9AM – 10:30AM

